van Rhijn Bas W G, van der Kwast Theo H, Vis André N, Kirkels Wim J, Boevé Egbert R, Jöbsis Adriaan C, Zwarthoff Ellen C
Department of Pathology, Josephine Nefkens Institute, Erasmus MC, 3000 DR Rotterdam, the Netherlands.
Cancer Res. 2004 Mar 15;64(6):1911-4. doi: 10.1158/0008-5472.can-03-2421.
Fibroblast growth factor receptor 3 (FGFR3) and P53 mutations are frequently observed in bladder cancer. We here describe the distribution of FGFR3 mutations and P53 overexpression in 260 primary urothelial cell carcinomas. FGFR3 mutations were observed in 59% and P53 overexpression in 25%. Interestingly, FGFR3 and P53 alterations were mutually exclusive, because they coincided in only 5.7% of tumors. Consequently, we propose that they characterize two alternative genetic pathways in urothelial cell carcinoma pathogenesis. The genetic alterations were reflected in the pathology and the clinical outcome, i.e., FGFR3 mutations were found in low-stage/-grade tumors and were associated with a favorable disease course, whereas P53 alterations were tied to adverse disease parameters.
成纤维细胞生长因子受体3（FGFR3）和P53突变在膀胱癌中经常被观察到。我们在此描述260例原发性尿路上皮细胞癌中FGFR3突变和P53过表达的分布情况。59%的病例观察到FGFR3突变，25%的病例观察到P53过表达。有趣的是，FGFR3和P53改变相互排斥，因为它们仅在5.7%的肿瘤中同时出现。因此，我们认为它们代表了尿路上皮细胞癌发病机制中的两种不同遗传途径。这些基因改变反映在病理学和临床结果中，即FGFR3突变见于低分期/低分级肿瘤，并与良好的病程相关，而P53改变则与不良的疾病参数相关。
